secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062968
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara suspends VAL-083 after GBM AGILE failure; Q1 net loss $3M, cash $0.2M
-----------------------------------------------------------------------------

- Topline GBM AGILE results showed VAL-083 did not perform better than standard of care; development suspended.
- Focus shifts to REM-001 for cutaneous metastatic breast cancer; SBIR grant of $2.0M from NIH to support study.
- Cash and cash equivalents $0.2M at Sep 30, 2023; raised ~$1.0M net in Nov 2023 via ATM facility.
- Net loss $3.0M ($1.83/share) vs $4.6M ($3.39/share) in prior-year Q1; R&D and G&A expenses decreased.
- Company evaluating strategic options to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/0000950170-23-062968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023062968/ktra-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer